Stockscreener 앱 받기
0.7205
5.75%
-0.0476
전일 마감가:
$0.7681
열려 있는:
$0.7636
하루 거래량:
398.85K
Relative Volume:
0.79
시가총액:
$89.14M
수익:
-
순이익/손실:
$-198.64M
주가수익비율:
-0.4475
EPS:
-1.61
순현금흐름:
$-173.78M
1주 성능:
-8.43%
1개월 성능:
-29.03%
6개월 성능:
-67.24%
1년 성능:
-50.76%
1일 변동 폭
$0.72
$0.7736
1주일 범위
$0.72
$0.8216
52주 변동 폭
$0.72
$5.195
Invivyd Inc Stock (IVVD) Company Profile
명칭
Invivyd Inc
전화
(781) 819-0080
주소
1601 TRAPELO ROAD, WALTHAM
IVVD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| IVVD | 0.7231 | 89.14M | 0 | -198.64M | -173.78M | -1.61 |
| VRTX | 450.34 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.04 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.88 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.61 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.38 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-19 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | 개시 | H.C. Wainwright | Buy |
Invivyd Inc 주식(IVVD)의 최신 뉴스
Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates - MSN
HC Wainwright Issues Pessimistic Forecast for Invivyd (NASDAQ:IVVD) Stock Price - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October - MarketBeat
Invivyd, Inc. (NASDAQ:IVVD) Q3 2024 Earnings Call Transcript - Insider Monkey
Invivyd Inc (IVVD) Quarterly 10-Q Report - Quartz
Invivyd’s Q3 2024: Revenue Growth and Strategic Developments - TipRanks
IVVD stock touches 52-week low at $0.81 amid market challenges - Investing.com India
Invivyd earnings missed by $0.18, revenue fell short of estimates - Investing.com Canada
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor - The Manila Times
Invivyd's PEMGARDA Shows Promise Against COVID Variants Despite Lab Data Dispute | IVVD Stock News - StockTitan
Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect - Yahoo Finance
Invivyd (IVVD) Set to Announce Earnings on Thursday - Defense World
FMR LLC's Strategic Reduction in Invivyd Inc Shares - GuruFocus.com
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Upload - The Manila Times
Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term - The Bakersfield Californian
Invivyd's COVID Drug Shows 84% Risk Reduction in Phase 3 Trial, Secures FDA Authorization | IVVD Stock News - StockTitan
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - The Manila Times
Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire Inc.
Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024 - The Manila Times
Invivyd (IVVD) Sets Q3 2024 Earnings Call: Financial Results & Business Updates Coming Nov 14 | IVVD Stock News - StockTitan
EF Hutton Initiates Coverage of Invivyd (IVVD) with Buy Recommendation - MSN
Invivyd (NASDAQ:IVVD) Upgraded at EF Hutton Acquisition Co. I - Defense World
Invivyd (NASDAQ:IVVD) Upgraded by EF Hutton Acquisition Co. I to "Strong-Buy" Rating - MarketBeat
Invivyd reports preliminary Q3 PEMGARDA product revenue $9.3M - MSN
HC Wainwright Reiterates "Buy" Rating for Invivyd (NASDAQ:IVVD) - MarketBeat
Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Part - The Manila Times
Invivyd, Inc. Withdraws Financial Guidance for the Year 2024 - Marketscreener.com
Head to Head Review: Prime Medicine (NYSE:PRME) and Invivyd (NASDAQ:IVVD) - Defense World
Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update - MarketBeat
Guggenheim upgrades Invivyd Inc (IVVD) stock to a Buy - Knox Daily
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024 - The Manila Times
Point72 Asia Singapore Pte. Ltd. Sells 40,079 Shares of Invivyd, Inc. (NASDAQ:IVVD) - Defense World
Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data - The Manila Times
Invivyd Inc: Rising -81.14% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Invivyd Inc [IVVD] Records 200-Day SMA of $2.5044 - Knox Daily
Duquesne Family Office LLC Takes $629,000 Position in Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Take off with Invivyd Inc (IVVD): Get ready for trading - SETE News
Invivyd reports stable pemivibart potency against SARS-CoV-2 By Investing.com - Investing.com Canada
Invivyd reports stable pemivibart potency against SARS-CoV-2 - Investing.com
Invivyd Inc (IVVD) is a good investment, but the stock may be undervalued - US Post News
Investor’s Toolkit: Key Ratios for Assessing Invivyd Inc (IVVD)’s Performance - The Dwinnex
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart) - ForexTV.com
Invivyd (IVVD) Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA - StreetInsider.com
Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated - Daily Guardian Canada
Invivyd, Inc.(NasdaqGM: IVVD) dropped from S&P Global BMI Index - Marketscreener.com
Acadian Asset Management LLC Acquires 474,301 Shares of Invivyd, Inc. (NASDAQ:IVVD) - MarketBeat
Biotech Co. Escapes Stock-Drop Suit Over COVID-19 Drug - Law360
Invivyd Inc (IVVD)’s highs and lows: A closer look at its stock price fluctuations - US Post News
We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate - Yahoo Finance
Invivyd Inc (IVVD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Invivyd Inc 주식 (IVVD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Adimab, LLC | 10% Owner |
Jan 19 '24 |
Sale |
3.95 |
5,000,000 |
19,750,000 |
21,687,906 |
1.80%
0.42%
자본화:
|
볼륨(24시간):